Tocilizumab-treated convalescent COVID-19 patients retain the cross-neutralization potential against SARS-CoV-2 variants
Gasdermin D as a cellular switch to orientate immune responses via IL-33 or IL-1β
High risk of autoimmune diseases after COVID-19